PMID- 37317722
OWN - NLM
STAT- Publisher
LR  - 20230615
IS  - 0973-3922 (Electronic)
IS  - 0378-6323 (Linking)
DP  - 2023 May 18
TI  - Validation and usability of modified palmoplantar psoriasis area and severity 
      index in patients with palmoplantar psoriasis: A prospective longitudinal cohort 
      study.
PG  - 1-8
LID - 10.25259/IJDVL_712_2022 [pii]
AB  - Background Palmoplantar psoriasis (PPP), a troublesome variant, does not have any 
      validated scoring system to assess disease severity. Objective To validate 
      modified Palmoplantar Psoriasis Area and Severity Index (m-PPPASI) in patients 
      affected with PPP and to categorise it based on Dermatology Life Quality Index 
      (DLQI). Methods In this prospective study, patients with PPP aged > 18 years 
      visiting the psoriasis clinic at a tertiary care centre were included and 
      requested to complete DLQI during each visit at baseline, 2nd week, 6th and 12th 
      week. m-PPPASI was used by the raters to determine the disease severity. Results 
      Overall, 73 patients were included. m-PPPASI demonstrated high internal 
      consistency (alpha = 0.99), test-retest reliability of all three raters, that is, 
      Adithya Nagendran (AN) (r = 0.99, p < 0.0001), Tarun Narang (TN) (r = 1.0, p < 
      0.0001) and Sunil Dogra (SD) (r = 1.0, p < 0.0001) and inter-rater agreement 
      (intra-class correlation coefficient = 0.83). Face and content validity index for 
      items I-CVI = 0.845 were robust, and the instrument was uniformly rated as easy 
      to use (Likert scale 2) by all three raters. It was found to be responsive to 
      change (r = 0.92, p < 0.0001). Minimal clinically important differences (MCID)-1 
      and MCID-2 calculated by receiver operating characteristic curve using DLQI as 
      anchor were 2 and 35%, respectively. DLQI equivalent cutoff points for m-PPPASI 
      were 0-5 for mild, 6-9 for moderate, 10-19 for severe, and 20-72 for very severe 
      disease. Limitation Small sample size and single-center validation were the major 
      limitations. m-PPPASI doesn't objectively measure all characteristics of PPP such 
      as "fissuring" and "scaling" which could also be taken into consideration. 
      Conclusion m-PPPASI is validated in PPP and can be readily utilized by 
      physicians. However, further large-scale studies are needed.
FAU - Nagendran, Adithya
AU  - Nagendran A
AD  - Department of Dermatology Venereology and Leprology, SS Institute of Medical 
      Sciences and Research centre, Davanagere, Karnataka, India.
FAU - Hanumanthu, Vinod
AU  - Hanumanthu V
AD  - Department of Dermatology Venereology and Leprology, Post Graduate Institute of 
      Medical Education and Research (PGIMER), Chandigarh, India.
FAU - Dogra, Sunil
AU  - Dogra S
AD  - Department of Dermatology Venereology and Leprology, Post Graduate Institute of 
      Medical Education and Research (PGIMER), Chandigarh, India.
FAU - Narang, Tarun
AU  - Narang T
AD  - Department of Dermatology Venereology and Leprology, Post Graduate Institute of 
      Medical Education and Research (PGIMER), Chandigarh, India.
FAU - Venkata Maha Pinnaka, Lakshmi
AU  - Venkata Maha Pinnaka L
AD  - Department of Community Medicine & School of Public Health, Post Graduate 
      Institute of Medical Education and Research (PGIMER), Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20230518
PL  - United States
TA  - Indian J Dermatol Venereol Leprol
JT  - Indian journal of dermatology, venereology and leprology
JID - 7701852
SB  - IM
OTO - NOTNLM
OT  - Palmoplantar psoriasis
OT  - modified palmoplantar psoriasis area and severity index
EDAT- 2023/06/15 06:42
MHDA- 2023/06/15 06:42
CRDT- 2023/06/15 04:08
PHST- 2022/08/11 00:00 [received]
PHST- 2023/01/18 00:00 [accepted]
PHST- 2023/06/15 06:42 [medline]
PHST- 2023/06/15 06:42 [pubmed]
PHST- 2023/06/15 04:08 [entrez]
AID - 10.25259/IJDVL_712_2022 [pii]
AID - 10.25259/IJDVL_712_2022 [doi]
PST - aheadofprint
SO  - Indian J Dermatol Venereol Leprol. 2023 May 18:1-8. doi: 10.25259/IJDVL_712_2022.